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SUMMARY 
In five patients with terminal liver failure, replacement of the diseased liver with a 
well functioning homograft restored markedly depressed total complement and 
C4 and C3 to normal levels. Concomitantly, C5 protein also increased. Post-
operatively, two patients developed a marked drop in C4 and C3 probably in 
relation to homograft rejection. In contrast, serum hepatitis and biliary obstruc-
tion were not accompanied by significant changes. It is concluded that the liver is 
an important source of synthesis of C4, C3 and C5 and that complement assays 
might aid in otherwise equivocal diagnosis of hepatic homograft rejection. 
INTRODUCTION 
The investigation of the human serum complement system after orthotopic liver trans-
plantation must take into account a multiplicity of factors. First, the provision of a new 
homograft liver to a patient in hepatic failure makes it necessary to evaluate complement 
activity in relation to hepatic function. Secondarily, postoperative events such as graft 
rejection. biliary tract obstruction, and serum hepatitis, all might influence complement 
levels by immunological or non-immunological mechanisms. 
In this study the levels of total complement and several of its components were assayed in 
five hepatic homograft recipients. Excellent initial graft function was invariably obtained, 
but later all patients encountered at least one of the aforementioned postoperative com-
plications. 
MATERIALS AND METHODS 
Case material 
The five recipients were 15-47 years of age; prior to surgery all were in terminal liver failure 
due to cirrhosis (0T39 and 40), chronic hepatitis (OT36 and 41), and Wilson's disease 
(OT42). Orthotopic hepatic transplantation was carried out with standard techniques 
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(Starzl, 1969). In four of the five cases immunosuppression was provided with the triple 
drug regimen of azathioprine, prednisone and horse antilymphocyte globulin (Starzl, 
1969); the fifth patient (OT42) was given cyclophosphamide instead of azathioprine (Starzl 
et al., 1971). 
Postoperatively, Au-antigen was looked for in the recipient sera two or three times weekly 
utilizing standard detection methods (Torisu et al., 1971) as well as the complement fixation 
test (Sever, 1962; Shulman & Barker, 1969). 
Serum sampling 
Blood samples were collected once or twice before transplantation and at frequent inter-
vals postoperatively. Following clotting at room temperature for approximately I hr, serum 
was separated by centrifugation and stored at - 70C C until used. All sera from an individual 
patient were analysed simultaneously. 
Serum haemolytic complement assays 
Total complement activity was measured in 50% haemolytic units (CH50) according to 
Mayer (1961) and with the immune adherence haemagglutination (IA50) method of Nishioka 
(1963). The activity of Cl, C4, and C2 components were assayed by stoichiometric tube 
titration using EAC4hu, EACI hu, and EACI hUC4hu cells at a concentration of 1·5 x 108 cells 
per ml, respectively; the results were expressed in 50% haemolytic units (Nelson et at., 
1966; Borsos & Rapp, 1967). C3 activity was measured by immune adherence (Nishioka 
& Linscott, 1963) using EAC1 hUC4huC2hu cells. 
The C9 activity was titrated by immune haemolysis (Ruddy et al., 1971). The cellular 
intermediate (EACI-Shu cells) was prepared by incubating EAC1 hUC4hu cells in glucose 
gelatin Veronal buffer ([noue & Nelson, 1965) with C2, 3, 5, 6, 7, S complex of human 
complement for 30 min at 30°C followed by washing in gelatin Veronal buffer (Mayer, 
1961). 
The presence of serum anticomplementary activity (ACA) was assayed as previously 
described (Shulman & Barker, 1969; Torisu et al., 1971). 
The normal values for the various assays in our laboratory are included in Table 1. CH50 
and IA50 were measured in sera from 250 healthy blood donors, and C1, C4, C2, C3 and 
C9 were analysed in 100 of these specimens. 
Immunochemical assay 
Absolute weight concentration of the Clq subunit of CI (Lepow et al., 1963; Hanauer & 
Christian, 1967), C4, /31 E globulin (M uller-Eberhard & Biro, 1963), C3, /31 C globulin 
(Muller-Eberhard & Nilsson, 1960), and C5, (J I F globulin (Nilsson & Muller-Eberhard, 
1965) were measured by single radial immunodiffusion (Mancini, Carbonara & Heremans, 
1965; Kohler & Muller-Eberhard, 1967). Normal values (Kohler & ten Bensel, 1969) are 
included in Table I. 
RESULTS 
Changes with liver replacement 
Before transplantation, serum complement activity, as measured both with CH50 and 
IA50, was distinctly lower than normal in all five patients (Table 1). 
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Of the component activities, C4 and C3 were invariably low with C4 showing the most 
marked depression. Cl was subnormal in three of the patients. In contrast, C2 and C9 were 
within normal limits. Following replacement of the patients' diseased liver with a well 
functioning homograft, total complement, as well as C4 and C3 activities rose to normal 
within 1 week; Cl was less affected (Table 1, Fig. 1-3). 
The immunochemical measurement of C4 and C3 showed changes which paralleled the 
haemolytic titres but the alterations were less extreme. In two patients a slightly subnormal 
preoperative Clq rose to normal following transplantation; two other patients had normal 
levels throughout. The C5 protein rose from low normal to high normal or slightly elevated 
values in all four studied cases (Table I, Fig. 1-3). 
Subsequently, normal graft function was accompanied by normal complement levels 
(Fig. 1,2), except in one patient (OT42) who had supernormal total complement as well as 
C4 and C3 activities throughout the postoperative course (Fig. 3). 
Changes with homograft rejection 
Two of the recipients developed postoperative liver function abnormalities which were 
thought to be due to homograft rejection. In a patient with postnecrotic cirrhosis (OT40), 
hyperbilirubinaemia began 2 weeks postoperatively and progressed until death in liver 
failure and pulmonary sepsis at day 32. No Au-antigen could be found in the patient's 
serum. During the latter half of the postoperative course, total serum complement, and C3 
and C4 levels decreased progressively (Fig. 1). 
The original disease of the other patient (OT41) was chronic aggressive hepatitis without 
demonstrable Au-antigenaemia. Liver dysfunction indicative of rejection occurred approxi-
mately 3 weeks after transplantation and was accompanied by a marked temporary drop in 
CH50, IA50, C4 and C3 and a moderate decrease in C2 (Fig. 2). Later, persistent hyper-
bilirubinaemia in spite of anti-rejection therapy prompted re-exploration. At operation a 
biliary tract obstruction was diagnosed and surgically corrected but the patient succumbed 
16 days later. Before death, the complement levels again decreased with C4 being the most 
affected component. It was interesting that the liver had only minor histopathologic signs of 
rejection. 
In both patients the immunochemical studies revealed changes in the C4 and C3 com-
ponents mimicking the changes in the haemolytic titres. 
Changes with Au-antigen positive hepatitis 
One patient who was transplanted during active chronic Au-positive hepatitis (OT36) first 
converted to Au-negative but later became positive again concomitant with the appearance 
of liver dysfunction. The postoperative 'hepatitis' ran its total course from onset to full 
recovery from post-transplantation days 60 to 140 as fully reported elsewhere (Torisu et ai., 
1971). The maximum derangements of liver function included a bilirubin that rose to 14 
mg%, S.G.O.T. of 5000 IV, and total protein depression to less than 5 g%. 
When the post-transplantation liver dysfunction was most severe, a minor transient 
decrease in the complement levels occurred. Four weeks earlier, while graft function and 
complement levels were still normal, the anti-complement activity had risen to 1 :256 and at 
the time of the appearance of liver injury a titre of 1 :8 remained. 
The patient treated for Wilson's disease (OT42) developed Au-antigenaemia and abnormal 
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FIG. 1. Complement levels, liver function tests, and immunosuppressive treatment in a patient 
(OT40) who died of homograft failure caused by rejection (ALG-antilymphocyte globulin). 
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FIG. 2. The course in a patient (OT41) who developed liver dysfunction 3 weeks after opera-
tion which was thought to be due to rejection. Subsequently, biliary tract obstruction was 
diagnosed. Note the marked drop in total complement and several components concomitant 
with the rejection. 
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FIG. 3. Complement levels, Au-antigen assayed with complement fixation test and anti-
COillplement activity (reciprocals of titres), liver function tests and immunosuppressive treat-
ment in a patient (OT42) who developed Au-antigenaemia 6 weeks after transplantation. The 
deterioration in liver function was accompanied by a rise in anticomplement activity while 
complement levels were unaffected. 
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liver function tests 6 weeks after transplantation. At this time, complement levels remained 
unaffected while anticomplement activity rose significantly (Fig. 3). 
Both the last mentioned patients are still alive 12 and 4 months after transplantation with 
excellent liver function and normal and supernormal complement levels, respectively. 
The fifth patient (OT39), who suffered from Laennec's cirrhosis, had excellent homograft 
function until death from cerebrovascular insufficiency on the 26th postoperative day, 
although Au-antigenaemia was detected 5 days before demise. During the last days of life 
complement levels fell with C4 being the most affected component. Anticomplement acti-
vity was elevated (titres 1 : 4 and 1 : 32) throughout the postoperative course. 
DISCUSSION 
The site of synthesis of the specific proteins constituting the human complement system has 
been obscure. In the 1950s, two investigators using now abandoned methods reported sub-
normal (Jordan, 1953) and normal (Mandel & Lange, 1955) complement levels, respectively, 
in patients with cirrhosis. More recently, Inai et al. (1967) found markedly depressed 
CH50 and C4 in three out of thirty cirrhotic patients and speculated on a hepatic origin of 
C4. 
The extremely low preoperative complement levels in our five patients would be an 
indication of severely decompensated liver disease if a hepatic synthesis of complement could 
be proved. Circumstantial evidence that the liver is in fact a main site of synthesis was 
provided by the invariable restoration to normal levels of total complement, IA50 and some 
complement components after provision of a well functioning liver homograft. The C4 and 
C3 components were most markedly elevated and C5 also showed a significant increase. 
The fact that the changes in C4 function were more striking than those in the protein content 
could be attributed to some activation during handling. In contrast, no relation seemed to 
exist between hepatic function and the CI, Clq, C2 and C9 levels. Previously, a hepatic 
origin of C3 had been suggested by the observation of Alper and his associates (1969) who 
studied a liver transplant recipient whose C3 allotype changed to that of the donor. More-
over, the recent findings of Johnson, Alper, Rosen & Craig (1971) were consistent with a 
hepatic origin of C4. 
After the first postoperative week, several factors in addition to hepatic function came into 
prominence of which the most important appeared to be rejection. It has been shown by 
Austen & Russell (1964) and others (Guiney, Austen & Russell, 1964; Carpenter et a!., 
1967; Levine et al., 1970) that renal homograft rejection is accompanied by a fall in com-
plement. The data from two of our recipients of hepatic homo grafts showed the same 
pattern although interpretation in one of the cases was complicated by the fact that there was 
accompanying biliary tract obstruction. 
In patients rejecting renal homografts, there has been little argument that falls in com-
plement levels are due to an increased consumption by the immunologic reaction. This 
mechanism undoubtedly applies with hepatic homografts. However, an aggravating factor 
would be the coincident deterioration of hepatic function, if the liver were a site of comple-
ment synthesis as discussed above. Under these circumstances, the decline of complement 
components manufactured in the liver would be predicted to be considerably more drastic 
than during a comparable phase of renal homograft rejection. On the basis of limited obser-
vations this appeared to be the case, since the falls in total complement and C4 in patients 
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OT40 and OT41 were more severe than those reported in our kidney recipients (Yoko-
yamaetal.,1971). 
Assay of the complement system, and particularly C4, might be a sensitive diagnostic aid 
in differentiating hepatic homograft rejection from other forms of hepatic dysfunction. 
Normal complement has been reported to occur in acute viral hepatitis (Inai et al., 1967), 
unless the disease is complicated by arthritis (Alpert et al., 1971), a finding borne out in one 
of our recipients. Moreover, biliary obstruction that developed in another patient did not 
cause significant complement depletion. Finally, no essential artefact is introduced into the 
complement analysis by post-transplantation immunosuppressive therapy, as pointed out 
by Austen & Russell (1964) and confirmed in our own recent studies of renal transplant 
recipients (Yokoyama et al., 1971). 
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